According to Zhongtong Finance APP, Junshi Bio (01877) announced its interim performance for the six months ended June 30, 2024, with a total revenue of approximately 0.786 billion yuan, an increase of about 17% compared to the same period last year. Shareholders' losses amounted to 0.646 billion yuan, a decrease of about 35% compared to the same period last year. The total R&D expenditure was 0.546 billion yuan, a decrease of about 42% compared to the same period last year.

The company has a complete industry chain capability from the discovery and development of innovative drugs, clinical research worldwide, large-scale production, to commercialization, aiming to become an innovative pharmaceutical company based in China and expanding globally. The company adheres to the values of quality first, truth-seeking and pragmatic, integrity and compliance, and the pursuit of excellence. It is committed to researching and developing first-in-class or best-in-class drugs through original innovation and collaborative development. Through outstanding capabilities in drug discovery, strong biotechnology research and development capabilities, and large-scale production capabilities, the company has successfully developed a portfolio of pharmaceuticals with great market potential. One of the core products, Toripalimab (trade name: Tuoyi/LOQTORZI, code name: JS001), is the first domestically produced anti-PD-1 monoclonal antibody approved for marketing by the NMPA in China. As of the date of this announcement, it has obtained 10 indications in mainland China, and there are two sNDAs under review, many of which are the company's exclusive or leading indications. Toripalimab is also the first innovative biopharmaceutical developed and produced in China to be approved for marketing by the FDA and the only drug approved for the treatment of nasopharyngeal cancer in the United States. In addition to the United States, applications for the marketing of Toripalimab have been submitted in multiple countries and regions. The company's independently developed tifcemalimab is the world's first anti-tumor anti-BTLA monoclonal antibody to enter the clinical development stage (first-in-human). It has obtained FDA and NMPA clinical trial application approvals and is conducting two phase III registration clinical studies. In addition, multiple phase Ib/II clinical studies of tifcemalimab in combination with Toripalimab are ongoing, covering multiple tumor types.

With the continuous enrichment of the product pipeline and further exploration of drug combination therapy, the company's innovative areas have expanded to include small molecule drugs, peptide drugs, antibody-drug conjugates (ADCs), bispecific or multispecific antibody drugs, nucleic acid drugs, and other types of drug research and development. It also explores the next generation of innovative therapies for cancer, autoimmune diseases, and other diseases. Among them, the domestic sales revenue of the core product Tuoyi increased by about 50% compared to the same period of the previous year, and the losses significantly narrowed compared to the same period of the previous year. With the goal of "improving quality, reducing costs, and increasing efficiency", the company has made significant progress in controlling various costs, as well as in research and development, production, sales, and other aspects.